OncoZenge AB (publ) (STO:ONCOZ)

Sweden flag Sweden · Delayed Price · Currency is SEK
4.300
+0.020 (0.47%)
Apr 24, 2025, 4:49 PM CET
6.17%
Market Cap 50.13M
Revenue (ttm) 1,000.00
Net Income (ttm) -8.69M
Shares Out 11.71M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,940
Average Volume 51,324
Open 4.280
Previous Close 4.280
Day's Range 4.200 - 4.300
52-Week Range 2.800 - 12.100
Beta 1.46
RSI 36.52
Earnings Date May 16, 2025

About OncoZenge AB

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 2
Stock Exchange Nasdaq Stockholm
Ticker Symbol ONCOZ
Full Company Profile

Financial Performance

In 2024, OncoZenge AB's revenue was 1,000, a decrease of -66.67% compared to the previous year's 3,000. Losses were -8.69 million, -45.37% less than in 2023.

Financial Statements

News

There is no news available yet.